Home › All Companies › ASMB › Annual Report

ASSEMBLY BIOSCIENCES, INC. (ASMB) — Annual Report

AI-Powered SEC Filing Analysis

← All ASMB filings
Latest Annual Report Filed: 2026-03-19

Key Insights

  • The company has a collaboration agreement with Gilead Sciences, which provides a potential revenue stream and strategic partnership.
  • The company has conducted several private placements and at-the-market offerings to raise capital, indicating ongoing funding needs.
  • The company has a portfolio of clinical-stage drug candidates, including for the treatment of hepatitis B, which represents a potentially large market opportunity.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-19. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for ASSEMBLY BIOSCIENCES, INC.

Insider Trading Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.